Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

or it had a different mechanism of action. “There’s a lot of hype and excitement around GLP-1 and like medications,” Youssef. “And the thing I want to see is long-term safety data.

"GLP-1, a hormone that occurs naturally in the ... the compound may represent a unique treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

GLP-1 receptor agonists are pharmaceutical treatments primarily for T2D and more recently, obesity. They function by mimicking the action of GLP-1 hormone, which plays a crucial role in ...

More clinical trials on the direct and indirect effects of GLP-1s and their mechanisms of action are needed. As the body of research expands on the potential of glucagon-like peptide-1 receptor ...

ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that ... with tirzepatide, a GLP-1/GIP receptor co-agonist.” ...

The obesity market is growing at an unprecedented rate following the entrance of GLP-1 receptor agonists ... analogues and drugs with new mechanisms of action. There are 141 products in clinical ...

The firm’s analyst highlighted the drug’s differentiation due to its mechanism of action as an amylin receptor agonist and its potential advantages over the GLP-1 receptor class of drugs.